Federal Laboratory Consortium for Technology Transfer

Why an NDA Matters Before Discussing Federal Lab Technology

A conversation with a federal laboratory can be the first practical step toward licensing a new material, testing an engineering process, or commercializing research supported by public funds. It can also involve technical details that a company considers sensitive, including manufacturing methods, performance data, software architecture, prototypes, and plans for market entry. A non-disclosure agreement (NDA) helps establish expectations before those details are exchanged.

For businesses and entrepreneurs, the value of an NDA extends beyond preventing competitors from receiving confidential information. A well-drafted agreement creates a shared record of what the parties may disclose, how the recipient may use it, and which information must remain protected. This clarity can make early discussions more productive while preserving room for technical evaluation and commercial planning.

Federal technology transfer has additional considerations. A laboratory may have publication duties, public-record obligations, existing patent applications, prior disclosures, or limits on the promises its personnel can make. An NDA is therefore an important tool, but it is not a substitute for understanding the laboratory’s authority, the status of the technology, or the later licensing process.

Why timing matters before technical discussions

The best time to address confidentiality is before sensitive information changes hands. Once a company receives unpublished drawings, test results, source code, or process parameters, uncertainty about the terms of use can create friction. The recipient may be unsure whether it can share the material with an engineer, investor, manufacturer, or legal adviser. The laboratory may later question whether the information was handled appropriately.

An NDA gives the initial meeting a defined purpose. It can state that the parties are evaluating a possible research collaboration, license, cooperative development project, or other technology transfer arrangement. That purpose helps prevent information shared for evaluation from being redirected toward an unrelated product, competing research effort, or unapproved commercial activity.

Timing also matters for patent strategy. Public disclosure can affect patent rights in some jurisdictions and may complicate the assessment of novelty or filing deadlines. An NDA does not automatically prevent every disclosure problem, especially when other parties already know the information, but signing before a substantive exchange provides stronger evidence that the parties intended the material to remain confidential.

Businesses exploring federal inventions can also use resources such as the commercial potential guide to assess market fit and development risk while keeping the confidentiality discussion separate from broader technology evaluation.

What an effective NDA can protect

A useful agreement defines confidential information with enough precision to be meaningful. It may cover written documents, oral presentations, demonstrations, electronic files, physical samples, laboratory notebooks, experimental results, and information that is visibly marked confidential. If oral disclosures are included, the NDA should explain whether they must be summarized in writing within a stated period.

The agreement can protect technical and commercial information in the same framework. Technical material may include formulas, algorithms, test procedures, prototypes, specifications, and negative results. Commercial material may include pricing assumptions, customer research, regulatory plans, manufacturing partners, and investment strategy. Defining both categories prevents the parties from treating confidentiality as limited to patentable inventions.

An NDA should also describe permitted use. “Use only to evaluate a potential collaboration” is more helpful than a general promise to keep information secret. The permitted-use clause can identify who may receive the information, such as employees, contractors, attorneys, accountants, investors, or affiliated companies, provided those recipients have a legitimate need to know and are bound by appropriate confidentiality duties.

Standard exclusions are equally important. Information is commonly excluded when it was already known to the recipient without a duty of confidentiality, becomes public through no breach, is received lawfully from another source, is independently developed, or must be disclosed under law. These exceptions prevent an agreement from claiming control over knowledge that was never confidential in the first place.

Federal constraints that deserve attention

An NDA with a federal laboratory is not identical to a private-company confidentiality agreement. Federal employees may be subject to statutes, regulations, agency policies, records requirements, and disclosure obligations that cannot simply be waived by contract. The agreement should therefore acknowledge that it does not restrict lawful government operations or require a laboratory employee to violate a legal duty.

Public-record rules deserve careful review. Some information held by a federal agency may be subject to disclosure under applicable law, even if a private party would ordinarily treat it as confidential. An NDA may require the laboratory to provide notice when legally permitted and to cooperate in seeking protective treatment, but it cannot guarantee that every document will remain secret indefinitely.

The laboratory may also have already disclosed an invention through a patent filing, publication, conference presentation, government report, or prior conversation. A confidentiality agreement cannot restore secrecy to information that is already publicly available. Before sharing business-sensitive material, a company should ask what the laboratory considers unpublished, what has already been released, and whether third-party rights affect the discussion.

The agreement should identify the actual parties and their authority. A laboratory scientist may be an essential technical contact without having authority to grant patent rights, promise exclusivity, approve a license, or commit the agency to a commercial arrangement. Those decisions generally require review by an authorized technology transfer or contracting office.

Terms to negotiate before sharing information

The duration of confidentiality is one of the most visible terms, but it should be matched to the information involved. A fixed period may be practical for early evaluation, while trade-secret information may require protection for as long as it remains a trade secret. The parties should distinguish the period for disclosing information from the period during which confidentiality obligations continue.

The agreement should address copies, storage, cybersecurity, and return or destruction. A recipient may need to retain one archival copy for legal compliance, insurance, audit, or recordkeeping purposes. At the same time, the NDA can require reasonable security controls, limit downloads, restrict access to approved personnel, and establish what happens when discussions end.

Remedies and dispute provisions require particular care in a federal setting. A private contract may contain liquidated damages, broad indemnification, or a chosen court, but those provisions may be unsuitable or unavailable when a federal agency is involved. The laboratory’s counsel or technology transfer office can explain which terms are permissible and which must follow agency rules.

The agreement should also clarify what it does not do. It should not grant a license, transfer ownership, promise future funding, establish exclusivity, or require either party to proceed with a transaction. If the company needs rights to test, make, use, or sell a technology, those permissions belong in a separate license, research agreement, or other authorized instrument.

Choosing the right protection for the discussion

An NDA is often the right starting point, but it is not the only mechanism for managing sensitive information. Some discussions can begin with publicly available patent information and a high-level description of the company’s needs. More detailed exchanges may then require a mutual NDA, a one-way NDA, or a formal agreement tied to laboratory access and testing.

Situation Practical protection Key point to verify
The laboratory will disclose unpublished technical details One-way or mutual NDA Whether oral, visual, and electronic disclosures are covered
Both sides will share proprietary business and research information Mutual NDA Whether each party has comparable duties and permitted uses
A company needs to test a prototype or sample NDA plus material transfer or testing agreement Ownership, safety, handling, data rights, and publication terms
The parties will conduct joint research Research or collaboration agreement with confidentiality terms Intellectual property ownership, inventions, funding, and reporting
The company wants to commercialize the invention NDA followed by a license negotiation Field of use, royalties, diligence, exclusivity, and patent rights

A one-way NDA can be appropriate when the laboratory is disclosing nearly all of the sensitive material and the company is contributing little proprietary information. A mutual NDA is more suitable when the company must reveal its product concept, manufacturing approach, customer data, or investment plans to obtain useful technical feedback.

The format should reflect the next step. If the parties will exchange only documents, an NDA may be sufficient for the initial meeting. If they will transfer biological materials, operate equipment, inspect a facility, or generate new test data, additional agreements may be needed. Confidentiality language should work alongside those instruments rather than attempt to replace them.

Practical safeguards for a productive meeting

Preparation reduces the chance that an NDA becomes a source of delay. Before contacting a laboratory, a company can separate information into public, internally confidential, and highly restricted categories. It can then decide what the laboratory actually needs to know in order to assess technical fit, rather than disclosing its entire business plan at the first meeting.

Useful steps include:

A company should also maintain disciplined internal records after the meeting. A short written recap can identify the materials received, the agreed purpose, open questions, and any restrictions discussed. This record is useful if personnel change, negotiations pause, or a later license agreement needs to distinguish background information from newly created intellectual property.

The laboratory benefits from the same discipline. Clear labels, controlled distribution, and a designated technology transfer contact reduce misunderstandings and help technical staff focus on evaluating the invention. Good confidentiality practices support trust without suggesting that every conversation will automatically lead to a license or partnership.

Turning protected discussions into informed decisions

Once an NDA is in place, the parties can discuss technical performance, development barriers, manufacturing requirements, regulatory pathways, and potential customers with greater confidence. That information can help a company determine whether the invention is ready for commercialization, requires additional research, or fits better with a sponsored development arrangement.

Confidentiality should support careful due diligence rather than rush it. A company still needs to investigate patent ownership, government rights, competing technologies, market demand, regulatory obligations, production costs, and the laboratory’s expectations for licensing. The NDA protects the evaluation process; it does not establish that the technology is technically proven or commercially viable.

For organizations seeking federal technology, the Federal Laboratory Consortium network provides a practical route to relevant laboratories, available technologies, and technology transfer contacts. A prepared request, a narrowly defined business purpose, and a timely confidentiality discussion can help move an initial conversation toward a realistic evaluation plan.

Before sharing sensitive information, identify the authorized contact, define the intended use, and review the confidentiality terms with counsel familiar with intellectual property and federal agreements. A carefully tailored NDA can protect valuable information while keeping the discussion focused on the technical and commercial work required to turn federally developed research into a responsible market opportunity.